Entrada Therapeutics announced early clinical trial results for ENTR-601-44, an experimental treatment for people with Duchenne Muscular Dystrophy (DMD). The therapy is designed for patients who can benefit from “exon 44 skipping,” a genetic approach aimed at helping the body produce more dystrophin protein. Learn More: Mutations and Deletions Amenable to Exon 44 Skipping Therapies
However Entrada Therapeutics next-generation Duchenne therapy delivered disappointing results. Following the data announcement, the drug being developed for children with Duchenne Muscular Dystrophy fell significantly short of analysts’ expectations in an early- and mid-stage clinical trial, sending the company’s shares down more than 50% in premarket trading on Thursday.
Dystrophin is an important protein that helps keep muscles strong. People with DMD have very low or missing dystrophin, leading to progressive muscle weakness. Learn More: Dystrophin Gene
What Happened in the Study?
The Phase 1/2 ELEVATE-44-201 study included ambulatory boys and young men between 4 and 20 years old. Participants received either ENTR-601-44 or a placebo. Researchers mainly evaluated safety, dystrophin production, and physical function.
Main Findings
Researchers reported that:
- Entrada Therapeutics evaluated ENTR-601-44 in ambulatory boys aged 6 to 17 living with Duchenne Muscular Dystrophy caused by mutations amenable to exon 44 skipping.
- The Boston-based biotech reported that patients receiving treatment achieved a 2.36 percentage-point increase in dystrophin expression from a baseline level of 4%, restoring part of the critical muscle protein absent in Duchenne patients.
- In a research note published in April, William Blair analyst Myles Minter stated that a placebo-adjusted dystrophin increase of at least 10% represented the expected baseline scenario for the therapy, while the firm’s internal projections estimated approximately 11%.
- The findings also compared unfavorably with del-zota, Avidity Biosciences’ competing exon 44 skipping candidate, which previously demonstrated placebo-adjusted dystrophin gains of roughly 25% in a mid-stage clinical study — a level that Oppenheimer analysts had described as the benchmark for success for Entrada’s program.
- Ahead of the data release, Minter identified muscle delivery efficiency as the major concern for ENTR-601-44, and Entrada later disclosed that systemic drug exposure in pediatric patients was lower than anticipated relative to adult participants.
- Duchenne muscular dystrophy is a rare inherited neuromuscular disease that primarily affects boys and leads to progressive muscle degeneration over time.
- The study additionally showed a statistically significant improvement in the time required for treated participants to transition from the floor to a standing position, a commonly used functional assessment for monitoring muscle strength and predicting loss of ambulation.
- Entrada also confirmed that dosing has started in a second patient cohort receiving twice the original dose, with additional clinical results anticipated before the end of 2026.
What Makes This Therapy Different?
Entrada scientists believe their delivery technology may help the treatment reach muscle stem cells called satellite cells. These cells are important because they help repair damaged muscle and create new muscle fibers.
Researchers think this may explain why some patients experienced early functional improvements even though dystrophin increases were relatively modest.
What Happens Next?
All participants from the first group have now moved into the open-label portion of the study, where everyone receives the therapy. Researchers are also testing higher doses in additional patient groups.
Entrada expects more results later in 2026.
Follow This Page >>> All Clinical Trials for Duchenne
